1. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer
   Cathleen Nientiedt et al, 2021, Urologic Oncology: Seminars and Original Investigations CrossRef
2. Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay
   Nikolaos Nikoleousakos et al, 2021, Biomedicines CrossRef
3. Low Expression of SLC7A11 Confers Drug Resistance and Worse Survival in Ovarian Cancer via Inhibition of Cell Autophagy as a Competing Endogenous RNA
   Yao Ke et al, 2021, Front. Oncol. CrossRef
4. Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
   Nicola Cosgrove et al, 2022, Nat Commun CrossRef
5. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy
   Yizhu Xu et al, 2022, European Journal of Medicinal Chemistry CrossRef
6. Molecular profiling identifies distinct subtypes across TP53 mutant tumors
   Xin Chen et al, 2022 CrossRef
7. BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
   Sourat Darabi et al, 2022, Medicina CrossRef
8. PARP inhibitor olaparib induced differential protein expression in cervical cancer cells
   Jyotika Rajawat et al, 2023, Journal of Proteomics CrossRef
9. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors
   Curtis A. Clark et al, 2023 CrossRef
10. BRCA2 Frameshift Mutation in de novo Small-Cell Neuroendocrine Carcinoma of the Prostate: A Case Report
    Keisuke Okubo et al, 2023, Case Rep Oncol CrossRef
11. Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making
    Fabiana Perrone et al, 2024, Tumori CrossRef
12. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer
    M. Kordes et al, 2024, ESMO Gastrointestinal Oncology CrossRef